USFDA Inspection: Alembic Pharma gets form 483 with 5 procedural observations for Gujarat plant

The US Food and Drug Administration (USFDA) conducted inspection at Jarod-based solid oral formulation facility.

Published On 2024-11-25 10:17 GMT   |   Update On 2024-11-25 10:17 GMT
Advertisement

New Delhi: Alembic Pharmaceuticals on Saturday said the US health regulator has issued Form 483 with five observations after inspecting its Gujarat-based manufacturing plant.

The US Food and Drug Administration (USFDA) conducted inspection at Jarod-based solid oral formulation facility from November 14-22, 2024, the drug firm said in a regulatory filing.

Also Read: Alembic Pharma successfully completes USFDA inspection at Panelav Oncology formulation facility

Advertisement

The USFDA issued a Form 483 with five procedural observations, reports PTI.

The company will provide a comprehensive response to the USFDA for the observations within the stipulated period, it said.

Also Read: Alembic Pharma gets USFDA nod to Diltiazem Hydrochloride ER Capsules to treat hypertension

Alembic Pharmaceuticals is engaged in the development, manufacturing, and marketing of a wide range of pharmaceutical products. Founded in 1907 and headquartered in Vadodara, Gujarat, Alembic specializes in generic drugs, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company has a global presence, with operations in over 75 countries, including the U.S., Europe, and emerging markets. Alembic is known for its medicines across therapeutic segments such as cardiovascular, anti-infective, pain management, and oncology.

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News